USFDA completes audit of Dr Reddy's Louisiana-based facility

Image
Press Trust of India New Delhi
Last Updated : Aug 09 2019 | 11:55 AM IST

Dr Reddy's Laboratories on Friday said the US health regulator has completed audit of its Louisiana-based formulations manufacturing facility, following which no form 483 was issued.

The audit of our formulations manufacturing facility at Shreveport, Louisiana, USA by the the US Food and Drug Administration (USFDA), has been completed on August 8, 2019. No Form 483 was issued at the end of the inspection, the company said in a regulatory filing.

As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.

It notifies the company's management of objectionable conditions.

Shares of Dr Reddy's were trading 0.08 per cent higher at Rs 2,575 apiece on the BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 09 2019 | 11:55 AM IST

Next Story